Why Madrigal Pharmaceuticals, Inc. (MDGL) stock moved
Madrigal Pharmaceuticals, Inc. (MDGL) shares rose 0.2% to $431.16 at the November 2, 2026 close, a slight gain from the prior close of $430.36. That close is the latest confirmed price for MDGL; a live quote was not available. BestStocks flagged the session as a major change for MDGL. The move is tied to an earnings beat. Below, we break down what changed for MDGL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Madrigal Pharmaceuticals, Inc. (MDGL) reported EPS of $1.83 vs. consensus estimate of -$0.86, beating by 312.1% on November 3, 2026. MDGL earnings scheduled for February 18, 2027, with current consensus EPS estimate of -$0.11.
What it means for Madrigal Pharmaceuticals, Inc. investors
For Madrigal Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Earnings beat with positive market reaction; Positive 0.2% session move. Weighing against that: Madrigal Pharmaceuticals (MDGL) declined 2.60% to $455.03, driven primarily by technical weakness and valuation reassessment rather than operational news; Madrigal Pharmaceuticals filed an 8-K material event report today (SEC mdgl-20260730.htm) coinciding with an earnings report, triggering a 14.28% intraday decline to $468.76. BestStocks rates the overall signal quality low (41/100). With earnings due imminently, the next report is the most likely near-term test of the move.
MDGL price reaction
MDGL last traded at $431.16, up $0.80 (+0.19%) from the previous close of $430.36. Over the past month the stock has ranged between $430.36 and $496.45, and it currently sits about 1% of the way up that band.
The bull and bear case for MDGL stock
Weighing the constructive signals against the risks, here is how the bull and bear case for Madrigal Pharmaceuticals, Inc. (MDGL) lines up on the latest data.
The bullish case
- Earnings beat with positive market reaction.
- Positive 0.2% session move.
- Madrigal Pharmaceuticals rallied 10.48% to $476.35 following confirmation of today's earnings report filing.
The bearish case
- Madrigal Pharmaceuticals (MDGL) declined 2.60% to $455.03, driven primarily by technical weakness and valuation reassessment rather than operational news.
- MDGL fell 2.54% in early trading despite announcing that its collaboration with Ribo reached a first major milestone in advancing novel siRNA therapies for MASH (metabolic dysfunction-associated steatohepatitis).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Previous notable changes for MDGL
In-depth MDGL event analyses
Frequently asked questions about MDGL
Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock move?
MDGL rose 0.2% to $431.16. The move is associated with an earnings beat.
How much did MDGL stock rise?
MDGL gained 0.19% ($0.80) versus the prior close of $430.36, last trading at $431.16.
When is Madrigal Pharmaceuticals, Inc.'s next earnings date?
MDGL's next earnings report is scheduled for 2026-11-03 — about 0 days away.
How BestStocks tracks MDGL
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for MDGL, cross-checked against the data sources listed below. A live intraday quote was not available, so price and volume figures are the confirmed end-of-day close from November 2, 2026 — not the current price — and the percentage move is that session's. They refresh once live quotes resume. For companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.